Kraft Bryan D, Suliman Hagir B, Colman Eli C, Mahmood Kamran, Hartwig Matthew G, Piantadosi Claude A, Shofer Scott L
1 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine.
2 Department of Anesthesiology, and.
Am J Respir Crit Care Med. 2016 Mar 1;193(5):552-60. doi: 10.1164/rccm.201508-1634OC.
Central airway stenosis (CAS) after lung transplantation has been attributed in part to chronic airway ischemia; however, little is known about the time course or significance of large airway hypoxia early after transplantation.
To evaluate large airway oxygenation and hypoxic gene expression during the first month after lung transplantation and their relation to airway complications.
Subjects who underwent lung transplantation underwent endobronchial tissue oximetry of native and donor bronchi at 0, 3, and 30 days after transplantation (n = 11) and/or endobronchial biopsies (n = 14) at 30 days for real-time polymerase chain reaction of hypoxia-inducible genes. Patients were monitored for 6 months for the development of transplant-related complications.
Compared with native endobronchial tissues, donor tissue oxygen saturations (Sto2) were reduced in the upper lobes (74.1 ± 1.8% vs. 68.8 ± 1.7%; P < 0.05) and lower lobes (75.6 ± 1.6% vs. 71.5 ± 1.8%; P = 0.065) at 30 days post-transplantation. Donor upper lobe and subcarina Sto2 levels were also lower than the main carina (difference of -3.9 ± 1.5 and -4.8 ± 2.1, respectively; P < 0.05) at 30 days. Up-regulation of hypoxia-inducible genes VEGFA, FLT1, VEGFC, HMOX1, and TIE2 was significant in donor airways relative to native airways (all P < 0.05). VEGFA, KDR, and HMOX1 were associated with prolonged respiratory failure, prolonged hospitalization, extensive airway necrosis, and CAS (P < 0.05).
These findings implicate donor bronchial hypoxia as a driving factor for post-transplantation airway complications. Strategies to improve airway oxygenation, such as bronchial artery re-anastomosis and hyperbaric oxygen therapy merit clinical investigation.
肺移植术后中央气道狭窄(CAS)部分归因于慢性气道缺血;然而,对于移植后早期大气道缺氧的时间进程或意义知之甚少。
评估肺移植后第一个月内大气道氧合及缺氧基因表达情况及其与气道并发症的关系。
接受肺移植的受试者在移植后0天、3天和30天接受了对自身及供体支气管的支气管内组织血氧测定(n = 11)和/或在30天时接受支气管内活检(n = 14),用于缺氧诱导基因的实时聚合酶链反应。对患者进行6个月的监测以观察移植相关并发症的发生情况。
与自身支气管内组织相比,移植后30天时供体组织氧饱和度(Sto2)在上叶降低(74.1 ± 1.8%对68.8 ± 1.7%;P < 0.05),在下叶也降低(75.6 ± 1.6%对71.5 ± 1.8%;P = 0.065)。移植后30天时,供体上叶和隆突下Sto2水平也低于主隆突(分别相差 -3.9 ± 1.5和 -4.8 ± 2.1;P < 0.05)。相对于自身气道,供体气道中缺氧诱导基因VEGFA、FLT1、VEGFC、HMOX1和TIE2的上调具有显著性(均P < 0.05)。VEGFA、KDR和HMOX1与呼吸衰竭延长、住院时间延长、广泛气道坏死和CAS相关(P < 0.05)。
这些发现表明供体支气管缺氧是移植后气道并发症的驱动因素。改善气道氧合的策略,如支气管动脉重新吻合和高压氧治疗值得临床研究。